Ipamorelin released GH in men but missed in two bowel-recovery trials

How does ipamorelin work?

Ipamorelin is a synthetic pentapeptide that activates the ghrelin receptor (GHS-R1a) on pituitary somatotrophs, triggering a pulse of growth hormone release.

GHS-R1a is the same receptor family targeted by older growth-hormone-releasing peptides like GHRP-6. The receptor mechanism is plausible and established. What ipamorelin does over months of use in healthy adults is not.

Is ipamorelin selective for growth hormone?

In rats and swine, ipamorelin released growth hormone while leaving ACTH and cortisol essentially flat, even at doses more than 200-fold above the dose needed to release GH ^[1].

That was a real and useful pharmacological finding. It was the first demonstration that a ghrelin-receptor agonist can be tuned toward GH release without dragging the stress-hormone axis along for the ride.

The finding comes from one animal study in two species, using specific dose ranges and a specific dosing schedule. "Selective" in that context means selective relative to ACTH and cortisol co-release at the doses tested in those animals. It does not mean the receptor behaves identically across species, dose ranges, injection frequencies, or months of continuous use in a healthy adult.

The selectivity claim repeated across forums and vendor copy traces back almost entirely to that one foundational paper, not to a body of confirmatory work in the people now using ipamorelin.

What human studies of ipamorelin exist?

Three pieces of human data exist for ipamorelin, one pharmacokinetic study and two postoperative ileus trials, and none supports the fat-loss, recomposition, sleep, or anti-aging framing it is marketed for.

The pharmacokinetic and pharmacodynamic study gave 40 healthy male volunteers single doses at five infusion rates ^[3]. Ipamorelin triggered a GH pulse in humans, peaking around 40 minutes after dosing, with predictable, dose-proportional clearance and a half-life around 2 hours.

That study shows ipamorelin is bioactive in people and roughly how fast it clears. It measured no therapeutic endpoint, so it says nothing about efficacy for any outcome. Every dose was a single dose; nobody in that trial took ipamorelin daily for eight weeks.

What happened in ipamorelin's postoperative ileus trials?

Both of ipamorelin's controlled outcome trials, run by Helsinn Therapeutics in postoperative ileus, failed to beat placebo, and Helsinn discontinued the program.

Postoperative ileus is the temporary bowel paralysis some patients experience after abdominal surgery. The rationale was sound and preclinically supported: ipamorelin sped bowel recovery in a rat ileus model ^[4].

A Phase II RCT then enrolled 114 adults undergoing bowel resection and dosed them with IV ipamorelin twice daily ^[5]. Ipamorelin did not significantly reduce time to first tolerated meal compared with placebo (25.3 vs 32.6 hours, p=0.15), and no secondary endpoint reached significance. A larger follow-up trial (NCT01280344, n=320) also failed to demonstrate benefit and remains unpublished.

These are the only controlled human outcome trials for ipamorelin. Both were negative, in surgical patients dosed IV for days, not healthy adults injecting ipamorelin subcutaneously for months.

Is ipamorelin's "clean safety profile" backed by data?

Ipamorelin's "clean safety profile" claim draws on a rat and swine paper ^[1] and a single-dose study in healthy men ^[3], and neither tested chronic dosing.

The same two papers carry the "selective GH release without side effects" claim. Neither establishes safety or selectivity over chronic, repeated, self-administered dosing in adults optimizing for body composition. The closest thing to repeated human dosing data comes from surgical patients receiving IV doses for a clinical indication that failed to show benefit, a different route, population, and duration from community use.

Reported side effects include injection-site reactions, water retention, flushing, hunger, and paresthesia at higher GH exposure. Those reports come from clinical trial populations and pharmacological plausibility given the mechanism, not from controlled monitoring of the self-optimization population using ipamorelin. For the appetite effect across this receptor class, see what ghrelin agonists do to appetite.

Ipamorelin is sold research-use-only through an unregulated supply chain. The purity and dose accuracy of what people inject is its own unresolved variable, layered on top of an already thin evidence base.

Where does the 200 to 300 mcg ipamorelin dose come from?

The 200 to 300 mcg ipamorelin protocol is a community convention, not a studied regimen.

Forum and vendor guidance clusters around 200-300 mcg subcutaneously, once to three times daily, often timed around sleep or training and stacked with CJC-1295 for a "synergistic pulse." No published trial tested that regimen.

The closest human dosing data point is the single-dose PK study, which gave single infusions across a range of doses to characterize clearance, not a repeated daily protocol ^[3]. The surgical trials used IV dosing at 0.03 mg/kg twice daily ^[5], a different route and population entirely.

Does stacking ipamorelin with CJC-1295 work?

No trial has tested ipamorelin combined with CJC-1295 as a regimen, so the stack's claimed synergy is untested.

A ghrelin-receptor agonist and a GHRH analog act on different receptors in the same GH-release pathway, so additive or synergistic GH pulses are mechanistically reasonable. Reasonable is not the same as demonstrated. Nobody has run the combination through a controlled trial and measured what the two together do to GH or IGF-1 output versus either compound alone. The CJC-1295 and ipamorelin evidence review covers both compounds.

How much does ipamorelin raise IGF-1?

Nobody has measured IGF-1 in humans on a chronic ipamorelin regimen, and the one dataset that measured it, in rats, found no significant change ^[2].

In rats given daily subcutaneous ipamorelin for 15 days, bone growth rate increased in a dose-dependent way, but IGF-1, IGFBPs, and bone turnover markers did not significantly change ^[2]. That result is a notable disconnect between a GH-axis effect, faster bone growth, and the biomarker usually used as the proxy for "the GH pulse is working."

One rat study should not be over-read. It is still a real reason to be skeptical of confident claims about how much IGF-1 will rise at any dose.

What is still unknown about ipamorelin?

Chronic use in healthy adults is the central gap: no published data cover chronic subcutaneous ipamorelin dosing in healthy adults over weeks or months.

• GH and IGF-1 trajectories. No study has tracked GH or IGF-1 under repeated ipamorelin dosing in healthy adults.
• Metabolic effects. Insulin sensitivity and cardiovascular or metabolic markers are unmeasured under chronic dosing.
• Tolerability over time. Injection-site tolerability over weeks or months has not been studied.
• Long-term safety. Long-term safety of sustained GH/IGF-1 axis stimulation in healthy adults, as opposed to GH-deficient or surgical patients, has not been studied for ipamorelin at all.